Form 4: MYOMO Chief Medical Officer Sells Shares for Tax Obligations Following RSU Vesting

MYOMO, Inc.'s Chief Medical Officer, Harry Kovelman, sold 13,054 shares of common stock at $2.19 per share on June 30, 2025, to cover income taxes related to the vesting of restricted stock units.

Summary

• Harry Kovelman, Chief Medical Officer of MYOMO, Inc. (MYO), reported a transaction involving the sale of common stock.
• On June 30, 2025, Kovelman disposed of 13,054 shares of MYOMO common stock.
• The shares were sold at a price of $2.19 per share.
• The sale was solely to cover income taxes incurred from the vesting of restricted stock units (RSUs) on June 28, 2025.
• This transaction was executed pursuant to an irrevocable election made by Kovelman on May 12, 2025.
• Following this transaction, Harry Kovelman beneficially owns 140,618 shares of MYOMO common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction is a routine tax-related sale following RSU vesting, which is a common and expected event for executives and does not reflect a discretionary decision to sell shares.

Positives

• The vesting of restricted stock units (RSUs) on June 28, 2025, indicates a compensation event for the Chief Medical Officer, which is generally positive for employee retention and alignment of interests.

Negatives

• No inherently negative aspects are present as the sale was for tax purposes, a routine event following RSU vesting.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction is a routine event related to executive compensation and tax obligations, and it does not provide specific insights into broader industry trends or competitive dynamics within the medical device or healthcare technology sector.

Comparison to Industry Standards

• The sale of shares to cover tax liabilities upon the vesting of restricted stock units is a standard and common practice for executives across all industries, including the medical technology sector.
• This type of transaction is not indicative of a change in management's view of the company's prospects, unlike discretionary sales.

Related Party Transactions

• The transaction involves an insider (Chief Medical Officer Harry Kovelman) selling company stock, which is a related party transaction.

Stakeholder Impact

• Shareholders: The sale of 13,054 shares by an insider is a small percentage of total outstanding shares and is for tax purposes, so it is unlikely to have a significant direct impact on existing shareholders.
• Employees: The vesting of RSUs and subsequent tax-related sale is a standard part of executive compensation, which can positively impact employee morale and retention by demonstrating the value of equity compensation.

Key Dates

Keywords

MYOMO, MYO, Harry Kovelman, Chief Medical Officer, Insider Trading, Form 4, SEC Filing, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding